No Stock Yet
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15.The analyst says that following the recent pipeline reprioritization and p
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
On CNBC's "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ:XM) as a "long-term growth play." Analysts strongly agree, giving XM an Outperform consens
Cramer's Lightning Round: CRISPR Therapeutics Will Work Perfectly in This Market
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
3 Things About CRISPR Therapeutics That Smart Investors Know
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
JMP Securities Remains a Buy on Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 12.2% in December
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 10,480,00
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
A Look At The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
No Stock Yet